Clinical Trial Update: Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease [Phase 1]

View source ↗

Summary

This clinical trial is evaluating regulatory T-cell therapy in combination with low-dose interleukin-2 for steroid-refractory chronic graft-versus-host disease;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Regulatory T cell therapy (regulatory T cells)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Graft Versus Host Disease, Chronic GVHD | Phase 1 | Status: ACTIVE_NOT_RECRUITING